Litigation Details for Mallinckrodt IP v. InnoPharma Licensing LLC (D. Del. 2016)

« Back to Dashboard

Mallinckrodt IP v. InnoPharma Licensing LLC (D. Del. 2016)

Docket	1:16-cv-01116	Date Filed	2016-12-01
Court	District Court, D. Delaware	Date Terminated	2017-05-09
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	9,399,012
Link to Docket	External link to docket

Details for Mallinckrodt IP v. InnoPharma Licensing LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-01				External link to document
2016-11-30	17		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,399,012 82. (etg) (Entered:…December 2016 9 May 2017 1:16-cv-01116 830 Patent None District Court, D. Delaware	External link to document
2016-11-30	3		Notice with respect to U.S. Patent No. 9,399,012. Date of Expiration of Patent: September 11, 2031 with … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …December 2016 9 May 2017 1:16-cv-01116 830 Patent None District Court, D. Delaware	External link to document

Mallinckrodt IP v. InnoPharma Licensing LLC: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: August 5, 2026

Mallinckrodt IP Ltd. sued InnoPharma Licensing LLC in the U.S. District Court for the District of Delaware after InnoPharma filed an abbreviated new drug application seeking approval for a generic version of OFIRMEV, Mallinckrodt’s intravenous acetaminophen product. The case, No. 1:16-cv-01116, was an ANDA patent dispute centered on U.S. Patent No. 6,992,096. The litigation ended without a publicly reported merits decision. The parties resolved the dispute through a confidential settlement and the action was dismissed.

What drug and patents were involved in Mallinckrodt v. InnoPharma?

The case concerned intravenous acetaminophen, marketed by Mallinckrodt under the brand name OFIRMEV.

Item	Detail
Brand product	OFIRMEV
Active ingredient	Acetaminophen
Dosage form	Intravenous injection
NDA holder at the time	Mallinckrodt Hospital Products Inc. and related Mallinckrodt entities
Defendant	InnoPharma Licensing LLC
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01116
Action type	Hatch-Waxman ANDA litigation
Primary patent	U.S. Patent No. 6,992,096
Generic applicant	InnoPharma Licensing LLC
Litigation outcome	Settlement and dismissal without a public merits ruling

Mallinckrodt alleged that InnoPharma’s ANDA filing constituted an act of infringement under 35 U.S.C. § 271(e)(2). The complaint followed the statutory process used when a generic applicant provides a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

What did U.S. Patent No. 6,992,096 protect?

U.S. Patent No. 6,992,096 covered an injectable acetaminophen formulation. The patent was directed to an aqueous formulation intended for parenteral administration and addressed formulation stability and degradation concerns associated with acetaminophen in solution.

The patent was commercially important because intravenous acetaminophen requires a formulation that can remain chemically stable during manufacturing, storage, and administration. Formulation constraints include acetaminophen concentration, solvent system, pH, degradation products, and container compatibility.

The patent’s commercial relevance was narrower than a basic composition patent covering acetaminophen itself. It protected a specific pharmaceutical formulation rather than the active ingredient generally. That distinction limited the scope of potential infringement to products meeting the relevant claim limitations.

Patent timeline

Event	Date
Patent application filing	2001
U.S. Patent No. 6,992,096 issued	Jan. 31, 2006
OFIRMEV FDA approval	Nov. 2, 2010
InnoPharma ANDA litigation filed	2016
Expected patent expiration	January 2021, subject to applicable patent-term adjustment
Expected pediatric-exclusivity impact	Potential extension of FDA approval restrictions beyond patent expiry if pediatric exclusivity applied

The precise end date for enforceability depends on the patent-term calculation recorded by the USPTO and the regulatory exclusivity information associated with the NDA. The patent was approaching expiration when the 2016 litigation began, which reduced the remaining commercial period available to Mallinckrodt.

Why did Mallinckrodt sue InnoPharma?

Mallinckrodt sued to block FDA approval of InnoPharma’s proposed generic intravenous acetaminophen product before the expiration of the asserted patent.

Under the Hatch-Waxman framework, an ANDA applicant may challenge an Orange Book-listed patent through a Paragraph IV certification. The brand company can then file suit within 45 days. A timely suit generally triggers an automatic 30-month stay of FDA approval, subject to court orders or other statutory exceptions. The litigation therefore gave Mallinckrodt additional time to protect OFIRMEV sales while the patent dispute was pending.

Mallinckrodt’s likely infringement theory was that the proposed InnoPharma product would practice the formulation limitations of the ’096 patent. InnoPharma’s expected defenses included:

• Non-infringement based on differences between the proposed generic formulation and the patent claims.
• Invalidity under 35 U.S.C. §§ 102 and 103.
• Possible written-description or enablement challenges under 35 U.S.C. § 112.
• An assertion that the patent was unenforceable, if supported by the record.
• Regulatory and claim-construction arguments concerning the scope of the formulation limitations.

No reported decision establishes how the Delaware court would have resolved those issues.

What was the litigation status and outcome?

The case did not produce a publicly reported claim-construction opinion, trial verdict, or Federal Circuit decision. The publicly known outcome was a settlement followed by dismissal.

Litigation issue	Public outcome
Complaint	Filed in the District of Delaware in 2016
Patent challenge	Based on InnoPharma’s ANDA filing
Markman ruling	No widely reported merits ruling
Trial	None publicly reported
Settlement	Yes
Settlement terms	Confidential
Final disposition	Dismissal
Generic launch date	Not publicly established by a merits judgment

The settlement likely gave Mallinckrodt a negotiated resolution of the Paragraph IV challenge while preserving some ability to delay or control generic entry. The public record does not establish the precise launch date, royalty structure, license terms, or restrictions imposed on InnoPharma.

A confidential settlement is materially different from a judgment upholding the patent. It does not establish that the ’096 patent was valid, infringed, or enforceable. It also does not create a judicial precedent for later generic applicants.

What was the Orange Book status of OFIRMEV?

OFIRMEV was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The relevant listed patent was U.S. Patent No. 6,992,096, associated with Mallinckrodt’s intravenous acetaminophen product.

The Orange Book listing gave Mallinckrodt the statutory basis to assert the patent against ANDA applicants filing Paragraph IV certifications. The listing did not itself resolve whether a generic product infringed the patent. It established the patent’s connection to the approved drug and required ANDA applicants to address the patent in their certifications.

The regulatory protection for OFIRMEV consisted of several separate elements:

1. Patent protection for the injectable formulation.
2. FDA approval exclusivity associated with the original NDA and any later regulatory designations.
3. The 30-month stay triggered by a timely Paragraph IV suit.
4. Potential pediatric exclusivity, if applicable to the listed product and patent.

Patent expiry and FDA exclusivity must be analyzed separately. Expiration of the ’096 patent would remove the patent-based barrier, but FDA exclusivity could independently affect approval timing.

How strong was Mallinckrodt’s patent estate for OFIRMEV?

Mallinckrodt’s OFIRMEV patent estate was commercially meaningful but time-limited.

Strengths

The ’096 patent targeted the formulation used in an injectable product rather than a broad therapeutic method. A generic applicant seeking approval for the same dosage form could face a meaningful infringement risk if the product reproduced the claimed formulation characteristics.

The patent also covered technical attributes that may be difficult to avoid while maintaining an acceptable intravenous acetaminophen product. Reformulating around a pharmaceutical stability patent can require changes to pH, excipients, concentration, manufacturing conditions, or degradation controls. Those changes may affect FDA comparability, product stability, or commercial performance.

Limitations

The patent did not prevent competition from all acetaminophen products. Oral, rectal, topical, and other dosage forms were outside the patent’s core commercial reach unless they practiced the asserted claims.

The patent was also close to its expected expiration when Mallinckrodt filed suit. A defendant could therefore gain leverage from the limited remaining patent term. If a generic applicant could obtain approval near the end of the patent period, the economic value of extended litigation would decline.

The public settlement prevents a definitive assessment of whether InnoPharma’s product would have been found to infringe or whether the patent would have survived invalidity challenges.

What generic entry risks existed for OFIRMEV?

The principal generic-entry risk was a formulation design-around or a successful Paragraph IV challenge.

Scenario 1: Settlement-controlled entry

This was the outcome reflected by the case disposition. InnoPharma obtained a negotiated resolution, but the public docket does not disclose the precise commercial entry terms.

Scenario 2: Patent expiry

Once the ’096 patent expired, the patent-based barrier to approval and launch ended. Other Orange Book patents or regulatory exclusivities could still affect timing, but the principal formulation patent no longer supported an injunction against an otherwise approvable generic.

Scenario 3: Successful invalidity or non-infringement defense

If InnoPharma had prevailed, FDA approval could have proceeded before the patent’s nominal expiry, subject to the regulatory status of the ANDA and any remaining listed patents or exclusivities.

Scenario 4: Design-around formulation

A generic applicant could seek to avoid infringement by using a formulation outside the asserted claim limitations. The commercial risk would then shift from patent litigation to FDA development, stability validation, manufacturing scale-up, and product comparability.

Which companies challenged OFIRMEV patents?

Mallinckrodt faced multiple generic challenges to OFIRMEV around the same period. Publicly reported defendants in related OFIRMEV patent litigation included InnoPharma and other generic manufacturers such as Amneal, Fresenius Kabi, Aurobindo, and Perrigo-related entities.

The multi-defendant litigation increased the likelihood that generic competition would reach the market after the applicable patent and exclusivity barriers expired. It also reduced the commercial value of settling with one applicant if other ANDA applicants remained active.

Did the case involve a biosimilar or a generic drug?

The case involved a conventional generic drug, not a biosimilar.

InnoPharma filed an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The product was a generic version of intravenous acetaminophen. Biosimilar litigation under the Biologics Price Competition and Innovation Act was not relevant because acetaminophen is a small-molecule drug.

The litigation therefore followed the Hatch-Waxman model:

• ANDA filing.
• Paragraph IV patent certification.
• Brand-company infringement complaint.
• Potential 30-month FDA approval stay.
• Settlement, judgment, or generic entry after patent resolution.

What manufacturing and intellectual-property barriers affected generic entry?

The principal technical barrier was reproducing a stable intravenous acetaminophen product without infringing the ’096 patent.

Manufacturing considerations included:

• Control of acetaminophen degradation products.
• Maintenance of formulation pH.
• Sterile manufacturing and aseptic processing.
• Container and closure compatibility.
• Shelf-life stability.
• Dose and concentration matching.
• FDA requirements for injectable products.
• Commercial-scale process reproducibility.

These issues create a distinction between legal design-around and practical design-around. A formulation may avoid a patent claim but still require substantial development work before FDA approval. Conversely, a formulation that is highly similar to OFIRMEV may reduce development risk while increasing infringement exposure.

How does the OFIRMEV patent dispute compare with method-of-use litigation?

The Mallinckrodt-InnoPharma dispute was primarily a formulation patent case. It did not present the same risk profile as a method-of-use case involving a narrow indication or dosing regimen.

Issue	OFIRMEV formulation dispute	Method-of-use dispute
Protected subject matter	Injectable composition and formulation characteristics	Treatment method, indication, dosing, or patient population
Main infringement question	Whether the generic product contains claimed formulation elements	Whether labeling induces or requires the patented use
Design-around option	Change formulation, excipients, pH, concentration, or process	Carve out patented indication or dosing information
FDA interface	Product sameness and injectable quality	Labeling and skinny-label strategy
Key commercial risk	Reproducing a technically difficult formulation	Liability from labeling or induced infringement

The formulation focus made the dispute relevant to the product itself. A generic applicant could not necessarily avoid risk through a simple label carve-out if the asserted claims covered the composition.

What were the licensing and settlement implications?

No publicly reported license agreement or settlement terms establish the economic arrangements between Mallinckrodt and InnoPharma.

In ANDA litigation, settlement structures can include:

• A license permitting entry on a specified date.
• An earlier entry date tied to another generic launch.
• Royalty-bearing supply or distribution arrangements.
• Restrictions on launch before patent expiry.
• Agreements involving authorized generic supply.
• Allocation of patent rights and manufacturing responsibilities.

Because the Mallinckrodt-InnoPharma settlement was confidential, the case should not be treated as evidence of a specific entry date or royalty obligation. Any commercial model must rely on later FDA approvals, product launch announcements, or regulatory filings rather than the dismissal itself.

What is the business impact of the litigation?

OFIRMEV was a branded hospital injectable product. Generic entry posed price and volume risks typical of institutional injectable markets, where formulary adoption, group purchasing organizations, hospital contracts, supply reliability, and shortages can materially affect substitution.

The exposure was concentrated in:

• Hospital and surgical settings.
• Postoperative pain management.
• Patients unable to take oral acetaminophen.
• Institutional purchasing contracts.
• Intravenous analgesic budgets.

The patent dispute protected only the injectable formulation and did not create exclusivity over acetaminophen as a therapeutic molecule. Once generic intravenous products became available, pricing pressure could increase rapidly if multiple manufacturers entered.

Key Takeaways

• Mallinckrodt IP v. InnoPharma Licensing LLC, No. 1:16-cv-01116, was a Hatch-Waxman dispute over generic intravenous acetaminophen.
• The principal asserted patent was U.S. Patent No. 6,992,096.
• The patent covered formulation technology associated with OFIRMEV, not acetaminophen generally.
• InnoPharma’s ANDA filing triggered patent litigation and the statutory approval-stay framework.
• The case ended in a confidential settlement and dismissal without a public validity, infringement, or claim-construction ruling.
• The patent’s limited remaining term in 2016 reduced the long-term value of continued litigation.
• Generic-entry risk remained high because multiple manufacturers pursued intravenous acetaminophen approval.
• The dispute involved a small-molecule generic, not a biosimilar.
• Public court records do not establish the settlement’s launch date, royalties, or license conditions.
• OFIRMEV’s commercial protection depended on the interaction of patent rights, FDA exclusivity, formulation complexity, and hospital-market execution.

FAQs About Mallinckrodt IP v. InnoPharma

Was Mallinckrodt’s OFIRMEV patent found valid?

No public merits decision in the InnoPharma case established that U.S. Patent No. 6,992,096 was valid, infringed, or enforceable. The case ended by settlement and dismissal.

Could InnoPharma launch a generic version of OFIRMEV before patent expiry?

The public docket does not establish the settlement’s permitted launch date. The case disposition alone does not prove whether InnoPharma launched before or after patent expiry.

Was U.S. Patent No. 6,992,096 a composition patent?

Yes. It covered an aqueous injectable acetaminophen formulation and related formulation characteristics rather than acetaminophen as a molecule.

Did the litigation concern intravenous or oral acetaminophen?

It concerned intravenous acetaminophen, marketed as OFIRMEV. Oral acetaminophen products were not the core subject of the dispute.

Did Mallinckrodt sue other generic companies over OFIRMEV?

Yes. Mallinckrodt pursued related ANDA litigation against multiple generic manufacturers seeking approval for intravenous acetaminophen products.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2010). OFIRMEV (acetaminophen) injection prescribing information. U.S. Department of Health and Human Services.

3. Mallinckrodt IP Ltd. v. InnoPharma Licensing LLC, No. 1:16-cv-01116, U.S. District Court for the District of Delaware.

4. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 6,992,096: Pharmaceutical compositions containing acetaminophen.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.